Indian drugmaker Zydus Cadila (BSE: 532321) has launched its Tenglyn (teneligliptin 20mg) tablets, which belongs to a new class of oral anti-diabetic agents dubbed gliptins. With an aim to make this important therapy affordable and accessible to ... Pharma Letter, 1 week ago
Drug launch to keep Cadila Health in focus - Hindu Business Line, 1 week ago
Zydus launches Tenglyn tablets in Indian market - Economic Times, 1 week ago
NEW DELHI: Zydus Cadila has received US health regulator's nod to initiate phase II clinical trials of Sarolitazar, its new drug for treating high fat levels in body due to diabetes, obesity, and sedentary habits. "United States Food and Drug ...Economic Times, 1 week ago Zydus gets FDA nod for clinical trials of Sarolitazar Daily Excelsior.com, 1 week ago
Operating revenue grew 17% to Rs 2460 crore and sales in US market grew 25% to Rs 1004 crore BS Reporter | Mumbai October 22, 2015 Last Updated at 23:13 IST Drug maker Zydus Cadila posted a 41 per cent growth in consolidated net profit at Rs 391 ...Business Standard India, 1 month ago Cadila Healthcare net profit surges 40% to Rs 391 crore in Q2 DNA India, 1 month ago
Moonje joins DDB Mudra West from Ogilvy & Mather, where he was a Creative Director BestMediaInfo Bureau | Mumbai | September 29, 2015 Nilay Moonje DDB Mudra Group has recently announced the appointment of Nilay Moonje as Group Creative ...Best Media Info, 2 months ago
Details Category: Small Molecules Published on Wednesday, 18 November 2015 09:24 Hits: 44 AHMEDABAD, India I November 18, 2015 I Zydus today announced that USFDA has endorsed company's plan to initiate a Phase 2 clinical trial of Saroglitazar ...PipelineReview, 1 week ago
LONDON, Nov. 26, 2015 /PRNewswire/ This report analyzes the worldwide markets for Biopharmaceuticals in US$ Million by the following Segments: Recombinant Protein, Monoclonal Antibodies (mAbs), Insulin, and Vaccines. The report provides separate ...Pharmacy Choice, 2 days ago
Opportunities in PCSK9 Inhibitors, CETP Inhibitors, MTTP Inhibitors, ApoB Inhibitors and PPAR Agonists What can be expected from the cholesterol-lowering drugs market? Which areas are going to grow at the fastest rates? This visiongain report ...Fat Pitch Financials, 4 days ago
More from: Ulitzer, Town Hall...and 22 other sources
MUMBAI: The health ministry plans to revamp guidelines for approving biosimilar drugs to make the regulatory pathway more robust and sync it with the rapidly evolving global landscape. The guidelines were released three years ago. Biosimilars are ...Economic Times, 1 week ago
Biosimilar market is projected to be worth USD 32 billion worldwide by 2025 According to 'Global Biosimilars Market, 2015-2025'
Dublin, Nov. 12, 2015 (GLOBE NEWSWIRE) -- Research and Markets ( http://www.researchandmarkets.com/research/b2mt8g/global ) has announced the addition of the "Global Biosimilars Market, 2015 - 2025" report to their offering. Overall, with the ...Franklin Credit Management Corporation, 2 weeks ago Contract Manufacturing in Pharmaceutical Industry, 2015-2025 - North America and Europe are the predominant regions where majority of the production facilities of CMOs are located Tutorial Finder, 2 weeks ago Biopharmaceutical Contract Manufacturing Market to 2025 - Market To Grow At An Annual Rate Of 8.3%, Driven By The Rapidly Expanding Biopharmaceutical Market And Technological Advancements Individual.com, 2 weeks ago Global Biosimilars Market Report, 2015-2025 - The biosimilar market is projected to be worth USD 32 billion worldwide by 2025 Ulitzer, 3 weeks ago
Many Indian drug companies have been facing warnings and have been issued bans by the United States Food and Drug Administration (US FDA) in recent years. They are looking to protect exports to US pharmaceuticals market. ...Pharmacy Choice, 1 month ago Drugmakers plan to get together to discuss how to get out of FDA warnings and bans Economic Times, 1 month ago
on your WebpageAdd Widget >Get your members hooked!